News

Oct 19, 2020 Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Oct 07, 2020 Registration Is Now Open For Atossa Therapeutics' Tribe Public Webinar Presentation and Q&A Event On October 13, 2020

Sep 21, 2020 Atossa Therapeutics To Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 22, 2020

Sep 17, 2020 Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Sep 01, 2020 Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19

Aug 26, 2020 Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020

Aug 17, 2020 Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19

Aug 13, 2020 Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Aug 03, 2020 Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19

Jul 30, 2020 Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen

<< < > >>